BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Viveiros P, Riaz A, Lewandowski RJ, Mahalingam D. Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC). Cancers (Basel) 2019;11:E1085. [PMID: 31370248 DOI: 10.3390/cancers11081085] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Wang Y, Zhou C, Liu J, Shi Q, Huang S, Yang C, Li T, Chen Y, Xiong B. Increased Liquefactive Necrosis Formation After Transarterial Chemoembolization Combined with Molecular Targeted Agents Plus Immune Checkpoint Inhibitors for Hepatocellular Carcinoma. Cancer Manag Res 2021;13:6935-41. [PMID: 34522136 DOI: 10.2147/CMAR.S328812] [Reference Citation Analysis]
2 Zheng L, Fang S, Wu F, Chen W, Chen M, Weng Q, Wu X, Song J, Zhao Z, Ji J. Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study. Front Mol Biosci 2020;7:609322. [PMID: 33521054 DOI: 10.3389/fmolb.2020.609322] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chen S, Chen H, Zhang Y, Li W. Efficacy and Safety of Cellular Immunotherapy by Local Infusion for Liver Tumor: A Systematic Review and Meta-Analysis. Front Oncol 2022;12:772509. [DOI: 10.3389/fonc.2022.772509] [Reference Citation Analysis]
4 Dai Y, Jiang H, Jiang H, Zhao S, Zeng X, Sun R, Zheng R. Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis. Transl Oncol 2021;14:101238. [PMID: 34628285 DOI: 10.1016/j.tranon.2021.101238] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Pinato DJ, Murray SM, Forner A, Kaneko T, Fessas P, Toniutto P, Mínguez B, Cacciato V, Avellini C, Diaz A, Boyton RJ, Altmann DM, Goldin RD, Akarca AU, Marafioti T, Mauri FA, Casagrande E, Grillo F, Giannini E, Bhoori S, Mazzaferro V. Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. J Immunother Cancer 2021;9:e003311. [PMID: 34593621 DOI: 10.1136/jitc-2021-003311] [Reference Citation Analysis]
6 Gupta M, Iyer RV. Hepatocellular Carcinoma: Special Issue Highlights. Cancers (Basel) 2020;12:E2026. [PMID: 32722037 DOI: 10.3390/cancers12082026] [Reference Citation Analysis]
7 Yan J, Ying X, Malhotra A, Talenfeld A, Charalel R, Lee KS, Trost D, Kesselman A. Safety and Efficacy of Microwave Ablation for Hepatocellular Carcinoma in the Setting of Transjugular Intrahepatic Portosystemic Shunt. Cardiovasc Intervent Radiol 2021. [PMID: 34859308 DOI: 10.1007/s00270-021-03012-y] [Reference Citation Analysis]
8 Kim KW, Van den Abbeele AD. Evolution of Transarterial Chemoembolization for the Treatment of Liver Cancer. Radiology 2019;293:704-6. [PMID: 31617799 DOI: 10.1148/radiol.2019192090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Kutlu R, Karatoprak S. Radioembolization for Hepatocellular Carcinoma in Downstaging and Bridging for Liver Transplantation. J Gastrointest Cancer 2020;51:1157-64. [PMID: 32880041 DOI: 10.1007/s12029-020-00492-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Zhang Y, Zhou H. LncRNA BCAR4 promotes liver cancer progression by upregulating ANAPC11 expression through sponging miR‑1261. Int J Mol Med 2020;46:159-66. [PMID: 32319544 DOI: 10.3892/ijmm.2020.4586] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 Xia F, Huang Z, Ndhlovu E, Zhang M, Chen X, Zhang B, Zhu P. The effect of the number of hepatic inflow occlusion times on the prognosis of ruptured hepatocellular carcinoma patients after hepatectomy. BMC Surg 2022;22. [DOI: 10.1186/s12893-022-01537-8] [Reference Citation Analysis]
12 Colquhoun SD. Hepatocellular carcinoma clinical update: Current standards and therapeutic strategies. Liver Research 2020;4:180-90. [DOI: 10.1016/j.livres.2020.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zheng L, Fang S, Wu F, Chen W, Chen M, Weng Q, Wu X, Song J, Zhao Z, Ji J. Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study. Front Mol Biosci 2020;7:609322. [PMID: 33521054 DOI: 10.3389/fmolb.2020.609322] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Wu YJ, Wei WC, Dai GF, Su JH, Tseng YH, Tsai TC. Exploring the Mechanism of Flaccidoxide-13-Acetate in Suppressing Cell Metastasis of Hepatocellular Carcinoma. Mar Drugs 2020;18:E314. [PMID: 32549236 DOI: 10.3390/md18060314] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 Zhang S, Lu Y, Jiang HY, Cheng ZM, Wei ZJ, Wei YH, Liu T, Xia BJ, Zhao XY, Huang Y, Zou X, Liu R, Zhou S. CircC16orf62 promotes hepatocellular carcinoma progression through the miR-138-5p/PTK2/AKT axis. Cell Death Dis 2021;12:597. [PMID: 34108451 DOI: 10.1038/s41419-021-03866-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Tovar-Felice G, García-Gámez A, Benito-Santamaría V, Balaguer-Paniagua D, Villalba-Auñón J, Sampere-Moragues J. Unresectable hepatocellular carcinoma treatment with doxorubicin-eluting polyethylene glycol microspheres: a single-center experience. Hepat Oncol 2021;8:HEP38. [PMID: 34408848 DOI: 10.2217/hep-2020-0035] [Reference Citation Analysis]
17 Li S, Chen L. Exosomes in Pathogenesis, Diagnosis, and Treatment of Hepatocellular Carcinoma. Front Oncol 2022;12:793432. [PMID: 35155236 DOI: 10.3389/fonc.2022.793432] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Chen H, Cheng H, Wu W, Li D, Mao J, Chu C, Liu G. The blooming intersection of transcatheter hepatic artery chemoembolization and nanomedicine. Chinese Chemical Letters 2020;31:1375-81. [DOI: 10.1016/j.cclet.2020.03.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
19 Tapadar S, Fathi S, Wu B, Sun CQ, Raji I, Moore SG, Arnold RS, Gaul DA, Petros JA, Oyelere AK. Liver-Targeting Class I Selective Histone Deacetylase Inhibitors Potently Suppress Hepatocellular Tumor Growth as Standalone Agents. Cancers (Basel) 2020;12:E3095. [PMID: 33114147 DOI: 10.3390/cancers12113095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Maestri M, Pallozzi M, Santopaolo F, Cerrito L, Pompili M, Gasbarrini A, Ponziani FR. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2033208] [Reference Citation Analysis]
21 Chen D, Li X, Li H, Wang K, Tian X. Identification of Immune-Related Prognostic mRNA and lncRNA in Patients with Hepatocellular Carcinoma. J Oncol 2022;2022:5313149. [PMID: 35027925 DOI: 10.1155/2022/5313149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Ahmed O, Pillai A. Hepatocellular Carcinoma: A Contemporary Approach to Locoregional Therapy. Am J Gastroenterol 2020;115:1733-6. [PMID: 33156085 DOI: 10.14309/ajg.0000000000000931] [Reference Citation Analysis]
23 Lu H, Gao L, Lv J. Circ_0078710 promotes the development of liver cancer by upregulating TXNDC5 via miR-431-5p. Ann Hepatol 2021;27:100551. [PMID: 34606982 DOI: 10.1016/j.aohep.2021.100551] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Delache O, Landreau A, Royer L, Petit A, Rousseau C, Rolland Y, Lalys F. A new software tool for planning interventional procedures in liver cancer. Minim Invasive Ther Allied Technol 2021;:1-10. [PMID: 34355657 DOI: 10.1080/13645706.2021.1954953] [Reference Citation Analysis]
25 Chen G, Chang M, Chang S, Ho Y, Chang H. Cytotoxicity and Apoptosis Induction of 6,7-Dehydroroyleanone from Taiwania cryptomerioides Bark Essential Oil in Hepatocellular Carcinoma Cells. Pharmaceutics 2022;14:351. [DOI: 10.3390/pharmaceutics14020351] [Reference Citation Analysis]